PDCD1 and skin squamous cell carcinoma: Responses to anti-PD-1 in SOT patients with cSCC (ORR 60.7%) were higher than that reported in clinical trials of non-SOT patients (ORR 35%–50%) and higher than in other case series of SOT patients with cSCC (73–75).